High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Année : 2023

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Marco Roncador
  • Fonction : Auteur
Anil Aktas Samur
Raphael Szalat
  • Fonction : Auteur
Masood Shammas
Adam Sperling
Anjan Thakurta

Résumé

Abstract High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviving myeloma cells by analyzing paired MM samples collected at diagnosis and relapse in the IFM 2009 study. We performed deep whole-genome sequencing on samples from 68 patients, 43 of whom were treated with RVD (lenalidomide, bortezomib, and dexamethasone) and 25 with RVD + HDM. Although the number of mutations was similar at diagnosis in both groups (7137 vs 7230; P = .67), the HDM group had significantly more mutations at relapse (9242 vs 13 383, P = .005). No change in the frequency of copy number alterations or structural variants was observed. The newly acquired mutations were typically associated with DNA damage and double-stranded breaks and were predominantly on the transcribed strand. A machine learning model, using this unique pattern, predicted patients who would receive HDM with high sensitivity, specificity, and positive prediction value. Clonal evolution analysis showed that all patients treated with HDM had clonal selection, whereas a static progression was observed with RVD. A significantly higher percentage of mutations were subclonal in the HDM cohort. Intriguingly, patients treated with HDM who achieved complete remission (CR) had significantly more mutations at relapse yet had similar survival rates as those treated with RVD who achieved CR. This similarity could have been due to HDM relapse samples having significantly more neoantigens. Overall, our study identifies increased genomic changes associated with HDM and provides rationale to further understand clonal complexity.
Fichier principal
Vignette du fichier
Samur et al Blood 2023 (1).pdf (3.26 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04265704 , version 1 (06-11-2023)

Identifiants

Citer

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, et al.. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood, 2023, 141 (14), pp.1724-1736. ⟨10.1182/blood.2022017094⟩. ⟨hal-04265704⟩
32 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More